TSL Thinksmart Limited

RNS Number:8676U
Tissue Science Laboratories PLC
16 April 2007



                                                                   16 April 2007

                  TSL R&D Teach-in For Analysts and Investors

Tissue Science Laboratories plc ('TSL' or the 'Company') (LSE: TSL), the medical
technology company specialising in biologic tissue replacement and repair
products, is holding a teach-in for analysts and investors today at 9:30am at
the London Stock Exchange.

In addition to representatives from the Company making presentations, two guest
speakers will be attending and speaking at the meeting - Dr Raymond Dunn, Chief
of the Division of Plastic and Reconstructive Surgery, University of
Massachusetts Medical School, and Dr Paul Sibbons of the Northwick Park
Institute of Medical Research. Dr Dunn will be speaking about the US biologics
market and how he sees this market gaining traction, as well as the benefits of
TSL's porcine collagen material, Permacol(R), from the surgeon's point of view.
Dr Sibbons will be speaking on current vascular graft products, why there is a
need for new products, and how TSL's developments in this field could provide
new options for surgeons.

Other topics covered throughout the morning will include an update on the
general surgery market, including TSL's progress in direct sales, market
penetration, distribution arrangements, reimbursements and the Company's US
market strategy. An overview of other projects will be provided, with a
technical update on the Permacol(R) material. There will also be an R&D overview
on the bone, ligament and vascular projects, including the market potential for
the individual products, the Company's progress in the development of these
projects, and a review of the proof of principal data achieved to date.

The teach-in will take place at the London Stock Exchange, 10 Paternoster Square
, London, EC4M 7LS and will commence at 9:30am. For those unable to attend,
presentation slides will be available on request by contacting the Hogarth
Partnership on tel: 020 7357 9477.
                                     -Ends-

Enquiries:

TSL plc                                         Tel: +44 (0) 1252 333 002
Martin Hunt, Chief Executive
David Jennings, Finance Director

Hogarth PR                                      Tel: +44 (0) 20 7357 9477
Melanie Toyne-Sewell/Sarah Richardson

Background on TSL

Tissue Science Laboratories plc ("TSL") is a medical technology company
specialising in tissue repair and replacement. Headquartered in Aldershot,
Hampshire, TSL floated in November 2001 and is listed on AIM (AIM: TSL).

TSL has a proprietary sheet product, derived from porcine dermis, called
Permacol(R). The Permacol(R) sheet product has been developed with a range of
unique properties to make it suitable for use in different applications,
including urology/gynaecology, complex and recurrent hernia repair, shoulder
rotator cuff repair and head and face repair and reconstruction. TSL sells
Permacol(R) directly in the complex and recurrent hernia surgical field and has
signed distribution agreements with CR Bard Inc (urology/gynaecology -
worldwide) and Zimmer Inc (orthopaedic - worldwide).

Different formulations of Permacol(R) have also been developed successfully,
including an injectable version, based on the same core technology. In addition,
TSL has built a development pipeline derived from other porcine tissues e.g.
bone, ligament and vascular that addresses the large and fast growing surgical
implant market.




                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
MSCBLGDSGUBGGRX

Grafico Azioni Thinksmart (LSE:TSL)
Storico
Da Lug 2024 a Ago 2024

Grafico Azioni Thinksmart (LSE:TSL)
Storico
Da Ago 2023 a Ago 2024